Cost and Clinical Analysis of Autologous Hematopoietic Stem Cell Mobilization with G-CSF and Plerixafor Compared to G-CSF and Cyclophosphamide
Paul Shaughnessy(CHRISTUS Transplant Institute), Peter A. McSweeney(Mesoblast (United States)), Maureen Hougham(CHRISTUS Transplant Institute), Sheryl Selvey(Massachusetts College of Pharmacy and Health Sciences), Matthew J. Silva(Washington University in St. Louis), Julie A. Murphy, Jill MacPherson(CHRISTUS Transplant Institute), Miguel Islas‐Ohlmayer(CHRISTUS Transplant Institute), Kurt Winkler(University of Education Upper Austria), Jeffrey Matous(Colorado Blood Cancer Institute), Michael B. Maris(Colorado Blood Cancer Institute), Michael Steinberg(Massachusetts College of Pharmacy and Health Sciences)
Cited by 88
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Osteosarcoma Relapse After Combined Modality Therapy: An Analysis of Unselected Patients in the Cooperative Osteosarcoma Study Group (COSS)
|Journal of Clinical Oncology|2005|654